The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The medical records of patients with hematogenous candidiasis at M. D. Anderson Cancer Center (Houston) between 1988 and 1992 were retrospectively reviewed. There were 491 episodes of infection (6 per 1,000 admissions), 79% of which occurred outside the intensive care unit setting. A significant decrease in incidence was observed among patients with leukemia over the study period, together with a relative decrease in Candida albicans and Candida tropicalis infections and an increase in Candida krusei and possibly Candida glabrata infections. In the multivariate analysis, fluconazole prophylaxis provided strong protection against the development of C. tropicalis infection (odds ratio [OR] = 0.08) and C. albicans infection (OR = 0.15), in comparison with protection against infections due to other species, but it was the single most important determinant for the relative increase in C. krusei (OR = 27.07) and C. glabrata (OR = 5.08) infections. In conclusion, there has been a substantial shift in the epidemiology of hematogenous candidiasis caused by different Candida species in recent years. Fluconazole appears to be playing a major role in this observed shift.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Changes in the species distributions of bloodstream isolates in hospitalized patients outside the ICU setting have also been reported (1, 20, 30).”
In the citing paper
“The effects of prior fluconazole use on the distribution of various Candida species causing BSI and, in particular, on the emergence of C. glabrata infections were previously demonstrated for patients with hematologic malignancies (1, 18), although other confounding risk factors have also been described (47, 48).”
In the citing paper
“Other North American and European investigators confirmed these observations in larger hospital settings [10, 11, 13, 20, 22, 25, 26].”
From Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000 (2004) · cites this paper as [10]
In the citing paper
“compared to other Candida species infections, the mortality rate associated with C. glabrata is the highest [19].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [19]
In the citing paper
“Although the association with fluconazole use and increased isolation of C. glabrata is well known (1, 10, 148, 311, 319), the evidence is strongest for cancer centers and less so for individual nonspecialty hospitals (11, 33, 131, 145, 147, 259).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [1]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fungemia in a Cancer Hospital: Changing Frequency, Earlier Onset, and Results of Therapy
Horn, R., Wong, B., Kiehn, T. E., & Armstrong, D. (1985) · Clinical Infectious Diseases · doi:10.1093/clinids/7.5.646 · Cited by 480
Candida tropicalis: A Major Pathogen in Immunocompromised Patients
WINGARD, J. R., MERZ, W. G., & SARAL, R. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-4-539 · Cited by 294
Systemic candidiasis in cancer patients.
Maksymiuk, A. W., Thongprasert, S., Hopfer, R. L., Luna, M. D. V., Fainstein, V., & Bodey, G. P. (1984) · PubMed · Cited by 271
Fluconazole and Candida krusei Fungemia
Girmenia, C., Pagano, L., Leone, G., & Martino, P. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.18.2267 · Cited by 19
Cited by
Items 101–139 of 139
Honey has an antifungal effect against Candida species
Irish, J., Carter, D. A., Shokohi, T., & Blair, S. E. (2006) · Medical Mycology · doi:10.1080/13693780500417037 · Cited by 160
Prophylactic antifungal therapy in the intensive care unit
Weinstein, R. A., Rex, J. H., & Sobel, J. D. (2001) · Clinical Infectious Diseases · doi:10.1086/319763 · Cited by 155
“Although other factors could be operative [23], prior antifungal therapy has been strongly linked to infection caused by these species [24, 25].”
BackgroundRisk factors for albicans and non-albicans candidemia in the intensive care unit*
Chow, J. K., Golan, Y., Ruthazer, R., Karchmer, A. W., Carmeli, Y., Lichtenberg, D. A., Chawla, V., Young, J. A., & Hadley, S. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31816fc4cd · Cited by 154
White, M. H. (1997) · Clinical Infectious Diseases · doi:10.1086/513661 · Cited by 151
Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital
GARBINO, J., KOLAROVA, L., ROHNER, P., LEW, D., PICHNA, P., & PITTET, D. (2002) · Medicine · doi:10.1097/00005792-200211000-00003 · Cited by 143
Shifting patterns in the epidemiology of nosocomial Candida infections
Snydman, D. R. (2003) · Chest · doi:10.1378/chest.123.5_suppl.500s · Cited by 142
Risk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough Candidemia
Uzun, O., Ascioglu, S., Anaissie, E. J., & Rex, J. H. (2001) · Clinical Infectious Diseases · doi:10.1086/320757 · Cited by 138
Self-citationTrends in Antifungal Use and Epidemiology of Nosocomial Yeast Infections in a University Hospital
Berrouane, Y. F., Herwaldt, L. A., & Pfaller, M. A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.531-537.1999 · Cited by 136
“tropicalis were more likely among patients who had not received that agent (1).”
BackgroundInfluentialSt-Germain, G., Laverdière, M., Pelletier, R., Bourgault, A.-M., Libman, M., Lemieux, C., & Noël, G. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.949-953.2001 · Cited by 134
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
Invasive candidiasis in immunocompromised hospitalized patients.
Sims, C. R., Ostrosky-Zeichner, L., & Rex, J. H. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.05.015 · Cited by 124
Role of dectin-2 for host defense against systemic infection with Candida glabrata
Ifrim, D. C., Bain, J. M., Reid, D. M., Oosting, M., Verschueren, I., Gow, N. A. R., van Krieken, J. H., Brown, G. D., Kullberg, B.-J., Joosten, L. A. B., et al. (2014) · Infection and Immunity · doi:10.1128/iai.01189-13 · Cited by 117
“MR recognizes the N-linked mannans of fungal cell walls, SIGNR-1 recognizes branched -mannans, and Galectin-3 recognizes -(1,2)-mannans (9–11).”
BackgroundIn Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine
Mitsuyama, J., Nomura, N., Hashimoto, K., Yamada, E., Nishikawa, H., Kaeriyama, M., Kimura, A., Todo, Y., & Narita, H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01159-07 · Cited by 111
“However, there is a great concern because of the increased prevalence of Candida glabrata isolates exhibiting reduced susceptibility to triazole antifungals and of Candida krusei, which has developed an intrinsic resistance to fluconazole and itraconazole due to the empirical use of triazole-based drugs, especially in…”
BackgroundAntifungal Susceptibility Testing of Candida Isolates from the Candida Surveillance Study
Lyon, G. M., Karatela, S., Sunay, S., & Adiri, Y. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02363-09 · Cited by 111
“Over the last 20 years, Candida species have become prominent nosocomial pathogens (1, 2, 21).”
BackgroundChi, H.-W., Yang, Y.-S., Shang, S.-T., Chen, K.-H., Yeh, K.-M., Chang, F.-Y., & Lin, J.-C. (2011) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2010.08.010 · Cited by 103
T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast
Shibata, T., Takahashi, T., Yamada, E., Kimura, A., Nishikawa, H., Hayakawa, H., Nomura, N., & Mitsuyama, J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05954-11 · Cited by 99
“There are still many mycoses which are hard to treat even with the application of these antifungal agents (1, 5, 21, 24, 25); accordingly, it is imperative that new antifungal agents be developed with broad-spectrum activities, novel mechanisms of action, and fewer side effects.”
BackgroundEarly treatment of candidemia in adults: a review
Ostrosky-Zeichner, L., Kullberg, B. J., Bow, E. J., Hadley, S., León, C., Nucci, M., Patterson, T. F., & Perfect, J. R. (2011) · Medical Mycology · doi:10.3109/13693786.2010.512300 · Cited by 97
Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit
Muñoz, P., Burillo, A., & Bouza, E. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00147-3 · Cited by 95
Safdar, A., van Rhee, F., Henslee-Downey, J., Singhal, S., & Mehta, J. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703252 · Cited by 93
Pfaller, M. A., Lockhart, S. R., Pujol, C., Swails-Wenger, J. A., Messer, S. A., Edmond, M. B., Jones, R. N., Wenzel, R. P., & Soll, D. R. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.6.1518-1529.1998 · Cited by 91
“9 kb (1, 10), which have been shown to be indicators of microevolution (10, 11).”
BackgroundConstant Low Rate of Fungemia in Norway, 1991 to 1996
Sandven, P., Bevanger, L., Digranes, A., Gaustad, P., Haukland, H. H., Steinbakk, M., & The Norwegian Yeast Study Group (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.12.3455-3459.1998 · Cited by 82
“Recently, it has also been reported from some institutions in the United States (1, 19, 24, 34) and also from other parts of the world (8, 9, 33) that there has been a shift in the Candida spp.”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Barton, R., Bijie, H., Bille, J., Chang, S.-C., da Luz Martins, M., Duse, A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.01.002 · Cited by 80
“Foremost among those species of Candida with decreased susceptibility to fluconazole is Candida glabrata (Abi-Said et al., 1997; Alexander et al., 2005; Arendrup et al., 2008; Hachem et al., 2008; Horn et al., 2009; Lee et al., 2009; Li et al., 2007; Malani et al., 2005; Nguyen et al., 1996; Pasqualotto et al., 2008;…”
BackgroundOutcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata
Blot, S., Vandewoude, K., Hoste, E., Poelaert, J., & Colardyn, F. (2001) · Journal of Hospital Infection · doi:10.1053/jhin.2000.0918 · Cited by 73
Kamran, M., Calcagno, A.-M., Findon, H., Bignell, E., Jones, M. D., Warn, P., Hopkins, P., Denning, D. W., Butler, G., Rogers, T., et al. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.2.546-552.2004 · Cited by 75
“The number of invasive life-threatening infections caused by the members of the fungal genus Candida has increased dramatically over the past 20 years (1, 2).”
BackgroundDavis, S. L., Vazquez, J. A., & Mckinnon, P. S. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h516 · Cited by 71
Joseph Baran Jr, B. M. (2001) · Scandinavian Journal of Infectious Diseases · doi:10.1080/003655401750065544 · Cited by 70
“The rise in the number of immunocompromised patients and the use of prophylactic antifungal agents have been suspected to play a major role in these changes, especially at large university-based oncology centers (5, 6).”
BackgroundResultHorn, D. L., Ostrosky-Zeichner, L., Morris, M. I., Ullmann, A. J., Wu, C., Buell, D. N., Kovanda, L. L., & Cornely, O. A. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0843-0 · Cited by 69
“Multivariate analyses have revealed additional, independent risk factors for candidemia: length of hospitalization, admission to and length of stay in an intensive care unit, the use of broad-spectrum antimicrobial agents, the presence of a vascular catheter, previous episodes of candidemia or bacteremia, Candida isol…”
BackgroundAnimal models in the analysis of Candida host–pathogen interactions
de Repentigny, L. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.06.001 · Cited by 69
Stéphan, F., Sialou Bah, M., Desterke, C., Rézaiguia‐Delclaux, S., Foulet, F., Duvaldestin, P., & Bretagne, S. (2002) · Clinical Infectious Diseases · doi:10.1086/344648 · Cited by 56
“to the increasing use of azole drugs [31], and the spread of”
BackgroundOude Lashof, A. M. L., Donnelly, J. P., Meis, J. F. G. M., van der Meer, J. W. M., & Kullberg, B. J. (2003) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-002-0854-6 · Cited by 49
“During the study period, there was a slight shift from cases of Candida albicans candidaemia to cases caused by non-Candida albicans species, but not as dramatic as in some hospitals in the USA [10, 20, 21 ].”
ResultMartins, N., Ferreira, I. C. F. R., Barros, L., Carvalho, A. M., Henriques, M., & Silva, S. (2015) · Industrial Crops and Products · doi:10.1016/j.indcrop.2014.12.033 · Cited by 48
“Opportunistic fungal infections, namely Candida species, comprise the most common deep pathogenic infections, being observed not only in immunocompromised patients, but also around the hospital and even in the rest of the population (Abi-Said et al., 1997; Eggimann et al., 2003; Li et al., 2006; Raman et al., 2013).”
BackgroundNosocomial Cluster of Candida guillermondii Fungemia in Surgical Patients
Masala, L., Luzzati, R., Maccacaro, L., Antozzi, L., Concia, E., & Fontana, R. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-1013-4 · Cited by 42
“[2, 3].”
Chronic Urinary Tract Infection Due to Candida utilis
Hazen, K. C., Theisz, G. W., & Howell, S. A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.824-827.1999 · Cited by 35
“In many cases, the newly recognized species are associated with fungemia, infected catheters, or onychomycosis (1, 8, 20).”
BackgroundSecular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital
Luzzati, R., Allegranzi, B., Antozzi, L., Masala, L., Pegoraro, E., Azzini, A., & Concia, E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01268.x · Cited by 33
“has been attributed by some authors to the widespread use of azoles [6,7,18,25–27]; nevertheless, others have failed to detect an increase in non-albicans Candida spp.”
BackgroundResultCandidaemia in a large teaching hospital: a clinical audit
Aliyu, S. H. (2006) · QJM · doi:10.1093/qjmed/hcl087 · Cited by 31
Two Cases of Fungemia due to Candida lusitaniae and a Literature Review
Viudes, A., Pemán, J., Cantón, E., Salavert, M., Ubeda, P., López-Ribot, J., & Gobernado, M. (2002) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-002-0713-5 · Cited by 29
Comert, F., Kulah, C., Aktas, E., Eroglu, O., & Ozlu, N. (2007) · Mycoses · doi:10.1111/j.1439-0507.2006.01309.x · Cited by 28
Antifungal Activity of Plant Secondary Metabolites on Candida albicans: An Updated Review
Khan, A., Moni, S. S., Ali, M., Mohan, S., Jan, H., Rasool, S., Kamal, M. A., Alshahrani, S., Halawi, M., & Alhazmi, H. A. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467215666220304143332 · Cited by 17
Moreira, A., Silva, S., Botelho, C., Sampaio, P., Pais, C., & Henriques, M. (2015) · Mycopathologia · doi:10.1007/s11046-015-9925-y · Cited by 10
“glabrata to fluconazole [28, 29].”
Metadata
- Authors
- Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Raad, Issam
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-06
- Volume
- 24
- Issue
- 6
- Pages
- 1122-1128
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2095696028
- Cited by
- 755
- References
- 4
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 5 · 2022: 11 · 2021: 3 · 2020: 14 · 2019: 9 · 2018: 8 · 2017: 18 · 2016: 10 · 2015: 21 · 2014: 28 · 2013: 17 · 2012: 35
- FWCI
- 22.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- Candida species, Candida albicans, Candida tropicalis, Candida krusei, Candida glabrata, fluconazole prophylaxis, leukemia, incidence trends, opportunistic fungal infection, cancer patients
- MeSH terms
- Adult, Aged, Candida, Candidiasis, Female, Humans, Male, Middle Aged, Retrospective Studies, Fluconazole, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.